The global CRISPR gene editing market size is calculated at USD 4.77 billion in 2025 and is expected to reach around USD ...

Intellia Therapeutics NTLA has put up a stellar performance in the past month. Shares of the company have rallied 29.8% ...

Gabriella Ngang, of Farmington Hills, is one of three in Michigan to take part in a clinical trial of a new sickle cell ...

Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) has continued to show benefits in sickle cell disease (SCD) ...

Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has announced a landmark partnership with the ...

CRISPR Therapeutics could stage a comeback thanks to clinical and commercial progress. There are many promising corporations ...

Sickle Cell Disease Market Insight, Epidemiology And Market Forecast - 2034The sickle cell disease treatment market is experiencing signific ...

A man who was the first person in the UK to receive a groundbreaking gene-editing therapy on the NHS, said he felt " ...

Vertex Pharmaceuticals' leap into the Russell 1000 Index marks its transformation from growth-focused biotech to blue-chip ...

The average Wall Street analyst following Editas Medicine ( EDIT 7.08%) thinks the gene therapy stock can reach $3.25 per share in the next year. From recent prices, this implies a gain of about 53% ...

Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...